Chinook marks an ignominious end for Sting
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Added firepower could signal a spending spree for Sanofi
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
Medtech venture backers play it safe
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
Biopharma venture investors shrug off Covid-19
First-quarter venture investments barely register the pandemic - huge cash reserves should protect funding for biotech start-ups this year.
Biopharma venture financing retreats, but not by much
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
How low can medtech venture investment go?
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Healx lands $56m to power artificial intelligence-led drug discovery
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
